High-affinity immunoglobulin epsilon receptor-bound IgE (FcεRI-bound IgE)

The FcεRI-bound IgE complex on mast cells and basophils is the primary molecular assembly responsible for initiating allergic inflammatory responses. This complex is formed when allergen-specific Immunoglobulin E (IgE) binds to the high-affinity IgE receptor (FcεRI) via its Fc region (Kraft & Kinet, 2007). In individuals sensitized to House Dust Mite (HDM) allergens, such as Der p 1 and Der p 2, these allergens cross-link the bound IgE molecules, triggering the aggregation of FcεRI (Thomas et al., 2010). This aggregation initiates an intracellular signaling cascade involving tyrosine kinases like Syk, leading to the rapid release of preformed mediators such as histamine and the synthesis of lipid mediators and cytokines (Gould & Sutton, 2008). This process is central to the pathogenesis of allergic asthma, rhinitis, and dermatitis. Therapeutic interventions, most notably omalizumab, target the IgE pathway by binding to free IgE and preventing its association with FcεRI, thereby reducing the density of the complex on cell surfaces and dampening the allergic response (FDA, 2023). Experimental therapies are also exploring the use of disruptors to dissociate IgE from the receptor after binding has occurred (Eggel et al., 2014).

Other names

IgE-FcεRI complexSensitized IgEHDM-specific IgE-FcεRI complexHigh-affinity IgE receptor-IgE complexFcεRI-bound IgE on mast cells and basophils recognizing HDM allergens

The primary mechanism involves the sequestration of free IgE antibodies to prevent their binding to the high-affinity IgE receptor (FcεRI) on mast cells and basophils (Gould & Sutton, 2008). This reduction in free IgE leads to a subsequent downregulation of FcεRI expression on the cell surface, effectively desensitizing the cells to allergens like house dust mites (Kraft & Kinet, 2007). Experimental agents may also act by actively disrupting the pre-formed IgE-FcεRI complex (Eggel et al., 2014).